Adage Capital Partners GP L.L.C. Takes Position in Evolus, Inc. $EOLS

Adage Capital Partners GP L.L.C. purchased a new position in Evolus, Inc. (NASDAQ:EOLS - Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 486,400 shares of the company's stock, valued at approximately $5,851,000. Adage Capital Partners GP L.L.C. owned about 0.75% of Evolus as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently bought and sold shares of EOLS. Price T Rowe Associates Inc. MD raised its position in shares of Evolus by 13.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 52,593 shares of the company's stock worth $581,000 after buying an additional 6,332 shares in the last quarter. Northern Trust Corp raised its position in shares of Evolus by 9.3% during the 4th quarter. Northern Trust Corp now owns 531,167 shares of the company's stock worth $5,864,000 after buying an additional 45,384 shares in the last quarter. Schonfeld Strategic Advisors LLC grew its stake in shares of Evolus by 62.6% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 34,700 shares of the company's stock worth $383,000 after purchasing an additional 13,363 shares during the last quarter. Comerica Bank acquired a new position in shares of Evolus in the 4th quarter worth approximately $312,000. Finally, Ameriprise Financial Inc. grew its stake in shares of Evolus by 11.4% in the 4th quarter. Ameriprise Financial Inc. now owns 80,446 shares of the company's stock worth $888,000 after purchasing an additional 8,214 shares during the last quarter. 90.69% of the stock is currently owned by institutional investors.

Insider Activity

In related news, insider David Moatazedi sold 16,582 shares of the stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $9.89, for a total transaction of $163,995.98. Following the completion of the sale, the insider owned 364,927 shares in the company, valued at $3,609,128.03. This trade represents a 4.35% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Brady Stewart acquired 30,000 shares of the stock in a transaction on Friday, August 15th. The stock was bought at an average price of $6.82 per share, with a total value of $204,600.00. Following the transaction, the director directly owned 88,629 shares in the company, valued at approximately $604,449.78. This represents a 51.17% increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 5.90% of the company's stock.

Evolus Stock Performance

Evolus stock traded down $0.14 during mid-day trading on Friday, reaching $7.38. The company had a trading volume of 194,428 shares, compared to its average volume of 1,080,716. The company has a quick ratio of 1.86, a current ratio of 2.27 and a debt-to-equity ratio of 22.00. Evolus, Inc. has a 52 week low of $5.71 and a 52 week high of $17.82. The company has a 50 day moving average of $8.12 and a 200-day moving average of $10.00. The firm has a market cap of $477.02 million, a price-to-earnings ratio of -7.53 and a beta of 1.07.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on EOLS shares. BTIG Research restated a "buy" rating and issued a $18.00 price target on shares of Evolus in a research report on Monday. HC Wainwright dropped their target price on shares of Evolus from $27.00 to $20.00 and set a "buy" rating on the stock in a research report on Wednesday, August 6th. Needham & Company LLC reissued a "hold" rating and issued a $22.00 target price on shares of Evolus in a research report on Wednesday, August 6th. Finally, Wall Street Zen downgraded shares of Evolus from a "hold" rating to a "sell" rating in a research report on Saturday, August 9th. Four equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $21.25.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.